The below screenshot is a tweet from Beth Milligan M.D., FAAFP and which is re-tweeted by the inventor of the mRNA technology, Robert W Malone, MD. The tweet states that for “FDA approval a vaccine must be >50% efficacious and should last at least 12 months. Pfizer is <40% and requires an injection every 6 months. This by definition does not meet FDA approval.”
The FDA has also performed a bait and switch, extending the Emergency Use Authorization for the Pfizer mRNA “vaccine” while approving a new “vaccine” called Comirnaty which will not be available until 2024. In this way, Big Pharma and the Government can enjoy blanket immunity, while fooling the general public into believing the mRNA “vaccine” is approved:
Quotes Directly from the FDA Site:
Will the emergency use authorization (EUA) for Pfizer-BioNTech COVID-19 Vaccine remain in effect after the approval?
The EUA will continue to cover adolescents 12 through 15 years of age and the administration of a third dose to certain immunocompromised individuals 12 years of age and older. Additionally, for logistical reasons, the EUA will continue to cover the use of the Pfizer-BioNTech COVID 19 Vaccine in individuals 16 years of age and older; this use is also now approved.
How is Comirnaty (COVID-19 VACCINE, mRNA) related to the PFIZER-BIONTECH COVID-19 VACCINE?
The FDA-approved Pfizer-BioNTech product Comirnaty (COVID-19 Vaccine, mRNA) and the FDA-authorized Pfizer-BioNTech COVID-19 Vaccine under EUA have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series without presenting any safety or effectiveness concerns. Therefore, providers can use doses distributed under EUA to administer the vaccination series as if the doses were the licensed vaccine. For purposes of administration, doses distributed under the EUA are interchangeable with the licensed doses. The Vaccine Information Fact Sheet for Recipients and Caregivers provides additional information about both the approved and authorized vaccine.
https://www.fda.gov/vaccines-blood-biologics/qa-comirnaty-covid-19-vaccine-mrna